NCT06411860 - A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

November 29, 2024

Study Completion Date

December 11, 2024

Conditions

Basic Science

Interventions

OTHER

Placebo

Participants will receive a subcutaneous (SC) injection of placebo.

DRUG

Olpasiran

Participants will receive a SC injection of olpasiran at dose level 1 or 2.

DRUG

Moxifloxacin

Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.

Trial Locations (1)

Fortrea Clinical Research Unit Limited - Leeds, Leeds